Anthera Pharmaceuticals, Inc. announced that Senior Vice President of Product Development Georgina Kilfoil has notified the company she will leave the company effective February 15, 2013 to pursue other opportunities. Dr. Colin Hislop, Anthera's Senior Vice President and Chief Medical Officer, will continue to oversee all product development related activities for blisibimod.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -98.51% |
2018 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index | CI |
2018 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-98.51% | 26 | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.56% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ANTH Stock
- News Anthera Pharmaceuticals, Inc.
- Anthera Pharmaceuticals Announces Departure of Senior Vice President of Product Development, Georgina Kilfoil